Report overview
Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.
This report aims to provide a comprehensive presentation of the global market for Somatostatin Analogue Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Somatostatin Analogue Drug. This report contains market size and forecasts of Somatostatin Analogue Drug in global, including the following market information:
Global Somatostatin Analogue Drug Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Somatostatin Analogue Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Octreotide Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Somatostatin Analogue Drug include Camurus AB, Chiasma, Ipsen Group, Boehringer Ingelheim International GmbH, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc. and Tarveda Therapeutics Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Somatostatin Analogue Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Somatostatin Analogue Drug Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Somatostatin Analogue Drug Market Segment Percentages, by Type, 2022 (%)
Octreotide
Lanreotide
Pasireotide
Global Somatostatin Analogue Drug Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Somatostatin Analogue Drug Market Segment Percentages, by Application, 2022 (%)
Acromegaly
Neuroendocrine Tumor (NET)
Others
Global Somatostatin Analogue Drug Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Somatostatin Analogue Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Somatostatin Analogue Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Somatostatin Analogue Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Camurus AB
Chiasma
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Tarveda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Somatostatin Analogue Drug, market overview.
Chapter 2: Global Somatostatin Analogue Drug market size in revenue.
Chapter 3: Detailed analysis of Somatostatin Analogue Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Somatostatin Analogue Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
